QPPV.COM KNOWLEDGE ASSESSMENT

Efalizumab: Mechanism, EU Withdrawal and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Efalizumab: Mechanism, EU Withdrawal and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A historical report describes progressive neurological symptoms during efalizumab exposure, but no MRI or JC-virus test results are available. What is the most appropriate pharmacovigilance approach?

Record suspected PML with the available evidence and seek diagnostic follow-up without coding it as confirmed. Classify the event as confirmed PML because the medicine was later withdrawn. Exclude the case because PML cannot be assessed without a positive cerebrospinal-fluid test. Attribute the symptoms to efalizumab because its mechanism affects immune surveillance.

Question 2 of 10 Which statement correctly distinguishes seriousness, expectedness and causality in an adverse event assessment?

They are separate assessments and should not be treated as interchangeable. A serious event is necessarily unexpected and causally related to the product. A listed event is necessarily non-serious and unrelated to the product. A population-level withdrawal decision determines all three for every individual case.

Question 3 of 10 Which statement correctly distinguishes the CHMP recommendation from the subsequent EU withdrawal?

The CHMP recommended suspension; the Commission decision withdrew the marketing authorisation. The CHMP withdrew the authorisation; the Commission later recommended suspension. Both were individual case causality decisions made by the treating specialists. The Commission action was a commercial discontinuation requested by the marketing authorisation holder.

Question 4 of 10 Why should prior and concomitant immunosuppressants be documented in a suspected PML or serious infection case?

They provide immune-context information relevant to evaluating the event and alternative explanations. They prove that efalizumab could not have contributed to the event. They replace the need to document diagnostic tests and clinical course. They determine whether the event should be coded as confirmed PML.

Question 5 of 10 Which statement best describes the EU indication for Raptiva before its withdrawal?

Selected adults with moderate-to-severe chronic plaque psoriasis who had failed, could not use or did not tolerate other systemic therapies. All patients with mild plaque psoriasis as first-line treatment. Patients with confirmed PML requiring antiviral treatment. Children with any inflammatory skin condition, regardless of prior therapy.

Question 6 of 10 A patient developed a serious infection while receiving efalizumab. Which approach is most consistent with sound pharmacovigilance practice?

Capture the infection details and assess causality without assuming that exposure proves the product caused it. Exclude the infection from review unless efalizumab is already considered the definite cause. Attribute the infection to efalizumab because immune effects are biologically plausible. Record only the organism and omit severity, treatment and outcome.

Question 7 of 10 Which interpretation best connects CD11a/LFA-1 blockade with both efalizumab's therapeutic effect and its safety context?

Blocking LFA-1 interactions could reduce psoriasis inflammation while also affecting immune surveillance. Blocking LFA-1 selectively eliminates JC virus and therefore prevents opportunistic infection. LFA-1 blockade directly causes every neurological event reported during treatment. The mechanism affects psoriasis only and provides no relevant context for infection risk.

Question 8 of 10 A reviewer is assessing an individual suspected PML case associated with efalizumab. Which statement correctly distinguishes that case assessment from the EU regulatory conclusion?

The population-level benefit–risk conclusion does not automatically establish causality in the individual case. The withdrawal decision establishes that efalizumab caused PML in every exposed patient with neurological symptoms. The individual case must be considered unrelated because the authorisation was withdrawn at population level. The regulatory conclusion replaces the need to assess diagnostic evidence in the case.

Question 9 of 10 Which description best explains efalizumab's pharmacological target and its relationship to LFA-1?

It is a humanised monoclonal antibody against CD11a, the alpha subunit of LFA-1. It is a small molecule that inhibits JC-virus replication within neural tissue. It is an antibody against CD20 that depletes circulating B cells. It is a cytokine replacement therapy that restores leukocyte activation.

Question 10 of 10 Which approach best supports an inspection-ready record of the Raptiva safety signal?

Maintain traceability from case intake through review, follow-up, coding, submission, signal evaluation and communication of decisions. Retain only the final signal conclusion and discard the supporting case records. Document regulatory communications but omit the medical assessment of individual cases. Combine the CHMP recommendation, Commission decision and individual causality assessments into one conclusion.

Efalizumab: Mechanism, EU Withdrawal and Pharmacovigilance — Knowledge Assessment

Cookie Settings